<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="49005">Deferasirox</z:chebi> is an orally administered, once-daily iron <z:chebi fb="0" ids="38161">chelator</z:chebi> with a generally good safety and efficacy profile </plain></SENT>
<SENT sid="1" pm="."><plain>Reported adverse events in the older myelodysplastic population are somewhat different to the more intensively investigated and younger thalassaemic population </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">Renal impairment</z:e> is the most concerning adverse event, but this is reversible if identified and the drug is withdrawn early </plain></SENT>
<SENT sid="3" pm="."><plain>Gastrointestinal effects, particularly diarrhoea, can be troublesome for older patients, but can be minimized with tailored therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Negative iron balance can be achieved in most patients with a median dose of 20 mg/kg/day, and doses up to 40 mg/kg are possible in patients with severe <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, who are at risk of <z:e sem="disease" ids="C0018802" disease_type="Disease or Syndrome" abbrv="CHF|chf">cardiac decompensation</z:e> </plain></SENT>
</text></document>